Effect of Thiazolidinediones (Glitazones) groups on Glycemic control and Lipid profile: A Meta-analysis of Randomized Control Trials
Journal Title: National Journal of Integrated Research in Medicine - Year 2012, Vol 3, Issue 1
Abstract
Background & objectives: In patients with type 2 diabetes mellitus, all therapeutic options should be evaluated for their effect on cardiovascular risk factors, in addition to glycemic control. Randomized controlled trials of pioglitazone and rosiglitazone in patients with type 2 diabetes to evaluate their effect on either glycemic control or serum lipid profile individually have been reviewed and analyzed but analysis of reports of effect on both these parameters simultaneously are very few and such meta-analysis has not been carried out earlier. This article presents meta-analysis of randomized controlled trials of pioglitazone and rosiglitazone in patients with type 2 diabetes to evaluate their effect on glycemic control as well as serum lipid profile. Methods: We identified the citations by searching the web site of MD-consult, National Library of Medicine and Google for identifying randomized controlled trails pertinent to the thiazolidinediones of interest (rosiglitazone and pioglitazone) and evaluated then compared effect of these two drugs on glycemic control and serum lipid profile by applying student’s t-test.Results: Twelve randomized controlled trials (n=10052) were identified. Both thiazolidinediones produced significant reduction in HbA1c and FPG. Pioglitazone significantly reduced TG and increased HDL-C levels without significant effect on LDL-C and Total CH; while rosiglitazone significantly increased HDL-C, LDL-C, Total CH and slightly increased TG. Comparatively, they did not differ in their effect on glycemic control but regarding lipid profile, pioglitazone significantly reduced TG whereas rosiglitazone slightly increased TG level. Rosiglitazone produced significantly more increase in LDL-C and total CH level as compared to pioglitazone. Interpretation & conclusion: Pioglitazone had significantly more beneficial effects on lipid profile than Rosiglitazones and is clinically superior in patient of Type-2 DM with dyslipidemia. [ Karelia B et al NJIRM 2012; 3(1) : 57-62].
Authors and Affiliations
Dr. Bharti. N. Karelia, Dr. Jatin . G. Buch
Keywords
Related Articles
- EP ID EP40186
- DOI -
- Views 341
- Downloads 0
A Study of Psychometric Properties Of Modified Rivermead Mobility Index
Background : To evaluate the effect treatment on mobility various studies have used. But responsiveness of Rivermaid mobility Index has found to be poor as items are scored on a dichotomous (yes/no) basis. MRMI is a mo...
A Craniometric Study of Adult Human Skulls From Andhra Pradesh
Background & Objectives: The human skull has been studied both metrically and non- metrically previously. Cranial index and other cranial indices are useful in differentiation of racial and gender difference. This stud...
Study of Management in Patient with Ectopic Pregnancy
Background: ectopic pregnancy has always challenged ingenuity of the Obstratrition and Gynaecologist by its bizarre clinical picture. If it is not attended in time, it may lead to maternal morbidity and mortality. It i...
Neonatal Septicemia: Bacterial Isolates & Their Antibiotics Susceptibility Patterns
Background: Septicemia remains a significant cause of morbidity and mortality in the newborn, more so in developing countries due to delivery and postnatal follow up in an unclean environment having more chance of conta...
Protective and curative effects of Livolin forte® on carbon tetrachloride-induced liver damage in Wistar rats
Objective: Livolin forte® (LIV) is a hepatoprotective drug that is being used in hospitals worldwide in the treatment and management of liver diseases. However, as it appear through the available published literature,...